Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital

European Journal of Cancer

Volumn 40, Issue 15, 2004, Pages 2230-2236

  Katopodis, Ourania ^a   Ross, Paul ^a   Norman, Andrew R ^a   Oates, Jacqui ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy related deaths; Colorectal cancer; Gastrointestinal cancer; Oesophagogastric cancer; Pancreatic cancer; Sixty day mortality; Vascular syndrome related mortality

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; INTERFERON; MITOMYCIN C; PLATINUM DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCULATION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CAUSE OF DEATH; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; GASTROINTESTINAL CARCINOMA; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNITED KINGDOM; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CONFIDENCE INTERVALS; ENGLAND; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 5344252377     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.04.008     Document Type: Article

References (23)

1. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:2000;1041-1047
2. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343:2000;905-912
3. Morton R.F., Goldberg R.M., Sargent D.J., et al. Oxaliplatin or CPT11 combined with 5FU/leucovorin in advanced colorectal cancer: An NCCTG/Calgb study. Proc. Am. Soc. Clin. Oncol. 20:2001;125a. (abstr. 495)
4. Goldberg M.R., Sargent D.J., Morton R.F., Mahoney M.R., Krook J.E., O'Connell M.J. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's Real-Time toxicity monitoring program. J. Clin. Oncol. 20:2002;4591-4596
5. Rothenberg M.L., Meropol N.J., Poplin E.A., Van Cutsem E., Wadler S. Mortality associated with Irinotecan plus bolus Fluorouracil/Leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19:2001;3801-3807
6. de Gramond A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2000;2938-2947
7. Goldberg R.M., Hatfield A.K., Kahn M., et al. Prospectively randomised North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the 1-isomer of intravenous leucovorin for the treatment of advanced colorectal cancer. J. Clin. Oncol. 15:1997;3320-3329
8. Leichman C.G., Flemming T.R., Franco M.M., et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J. Clin. Oncol. 13:1995;1303-1311
9. Petreli N., Douglas H.O., Herrera L., et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomised phase III trial. J. Clin. Oncol. 7:1989;1419-1426
10. Miller L., Emanuel D., Elfring G., Barker K., Saltz L. Evaluation of early mortality in patients receiving first - line chemotherapy for metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2002;. Abstract 515
11. Webb A., Cunningham D., Scarffe J.H., et al. Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxoroubicin and methotrexate in advanced oesophagogastric cancer. J. Clin. Oncol. 15(1):1997;261-267
12. Waters J.C., Norman A., Cunningham D., Scaffre J.H., et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomised trial. Br. J. Cancer. 80(1/2):1999;269-272
13. Ross P.J., Nicholson M., Cunningham D., et al. Prospective randomised trial comparing mitomycin, cisplatin, and protracted venous - infusion fluorouracil (PVI 5FU) with Epirubicin, Cisplatin, and PVI 5FU in advanced Esophagogastric cancer. J. Clin. Oncol. 20(8):2002;1996-2004
14. Tebbutt N.C., Norman A., Cunningham D., et al. A multicentre phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann. Oncol. 13:2002;1568-1575
15. Hill M., Norman A., Cunningham D., et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumour response, survival, and quality of life in advanced colorectal cancer. J. Clin. Oncol. 13(9):1995;2317-2323
16. Ross P., Norman A., Cunningham D., et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann. Oncol. 8:1997;995-1001
17. Price T., Cunningham D., Hickish T., et al. Phase II study of chronomodulated vs protracted venous infusional 5-FU both combined with mitomycin C in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;262a. (abstr)
18. Saini A., Norman A.R., Cunningham D., et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br. J. Cancer. 88:2003;1859-1865
19. Meta-analysis Group in cancer. Efficacy of intravenous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16, 301-308 (abstract)
20. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and Fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 17:1999;3553-3559
21. Chau I., Cunningham D. Chemotherapy in colorectal cancer: new options and new challenges. Br. M Bull. 64:2002;159-180
22. Haller D. New perspectives in the management of pancreas cancer. Sem. Oncol. 30(4):2003;3-10
23. Maisey N., Chau I., Cunningham D., et al. Multicentre randomised phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 6-FU plus Mitomycin in inoperable pancreatic cancer. J. Clin. Oncol. 20:2002;3130-3136